

WhiteSwell raises \$30M for heart failure treatment

21 December 2018 | News

Funds will support product development and clinical studies of novel catheter-based technology.



WhiteSwell, an Israeli-Irish medical technology startup company pioneering new ways to treat acute decompensated heart failure, has announced the close of a \$30 million series B funding round led by RA Capital Management and an InCube Ventures syndicate, with participation from other investors. Funds from the round will be used to support product development and a pivotal study of the company's innovative technology for the treatment of acute decompensated heart failure (ADHF).

The company also announced that WhiteSwell founder and chief technology officer Yaacov Nitzan has been joined by chief executive officer Eamon Brady and chief financial officer Seán Mac Réamoinn, who formerly served as chief executive officer and chief financial officer of Neuravi, a stroke treatment company acquired by Johnson & Johnson last year.

WhiteSwell is currently conducting an early feasibility study at clinical sites in the U.S., Israel and Europe.